News & Events zu Transcode Therapeutics Inc (RNAZ)RNAZTranscode Therapeutics Inc

TransCode Therapeutics Updates Clinical Data for TTX-MC138

TransCode Therapeutics announced updated clinical data from its Phase 1a clinical trial of TTX-MC138, its novel anti-miR-10b therapeutic candidate, in patients with relapsed or refractory, unresectable locally advanced, or metastatic solid tumors. At the data cutoff date of September 1, 2026, 10 of 14 efficacy-evaluable patients, or 71.4%, achieved stable disease as their best overall response by investigator assessment. In the context of a first-in-human, dose-escalation study enrolling patients with advanced, heavily pretreated cancers, the Company believes the consistency, breadth, and durability of disease control observed thus far are promising and warrant continued clinical evaluation. The disease control rate was 57.1% (95% confidence interval, 28.9% to 82.3%) at Cycle 3 Day 1 and 35.7% (95% confidence interval, 12.8% to 64.9%) at Cycle 6 Day 1. The durability of responses was also notable. Six of 14 efficacy-evaluable patients were progression-free at three months, three of 14 at six months, and three of 14 at nine and 12 months. Together, these findings show that the efficacy signal was not limited to a single assessment and included prolonged disease control in a subset of patients. As of the September 1, 2026, a total 98 doses have been administered. In this pre-specified data snapshot, TTX-MC138 demonstrated an acceptable tolerability profile in subjects with advanced solid tumors. No dose-limiting toxicities were reported, no treatment-emergent adverse events led to treatment discontinuation, including the highest evaluated dose level of 4.8 mg/kg. Of note, administration of TTX-MC138 for over a year was well tolerated and not associated with any dose-limiting toxicities. "The updated efficacy findings are highly positive and clinically meaningful for an early dose-escalation study in a heavily pretreated, heterogeneous advanced solid-tumor population," said Daniel Vlock, M.D., Medical Consultant for TransCode Therapeutics. "A 71% stable disease rate, disease control extending through six months, and three patients remaining progression-free at twelve months collectively demonstrate a compelling and durable signal of antitumor activity. Importantly, these efficacy findings were observed alongside continued tolerability and no reported dose-limiting toxicities, supporting further evaluation of TTX-MC138."

TransCode Therapeutics CFO Tom Fitzgerald Announces Retirement

TransCode Therapeutics announced the retirement of its CFO, Tom Fitzgerald. Fitzgerald has served as CFO since July 2018. Fitzgerald will resign as CFO and as a director of the company, effective immediately, after which he will continue to provide transition services to the company. John Tattory will serve as Interim CFO, effective immediately. Tattory started his career at Ernst &Young, then became Finance Director at Bristol-Myers Squibb and Tyco International. He was CFO of Cerapedics and Windtree Therapeutics. Currently, John is a Managing Director at Stout Risius Ross, a global advisory firm.